Value Report

Overview

The report presents Daiichi Sankyo’s fiscal 2017 progress toward its oncology-focused 2025 Vision, including clinical development of DS-8201 and other ADC candidates. It reports global edoxaban revenue of ¥77.1 billion for fiscal 2017. The Group also reports that its CO2 emissions were 7.1% lower than in fiscal 2015 and describes healthcare-access programs in Tanzania and China.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2017-2018
Period: 1 April 2017 – 31 March 2018
Language: English
Pages
File size
Restatement: Disclosed

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP
Other

Commitments

UN Global Compact
UN Guiding Principles
Science Based Targets initiative

Ratings

SBTi status

Materiality

Assessment
Basis

Assurance

Provider
Scope
Statement included
Metrics assured

Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services